phenol oropharyngeal (Cepastat, Ulcerease, Chloraseptic, Chloraseptic Warming Sore Throat Spray)

Dosing and uses of Cepastat, Ulcerease (phenol oropharyngeal)

• Adult
• Pediatric

 

Adult dosage forms and strengths

oral solution (mouthwash/gargle)

• 0.6% (Ulcerease)

oral solution (spray)

• 1.4% (Chloraseptic)

lozenge (oral)

• 14.5mg (Cepastat)

 

Sore Throat

Ulcerease: Gargle or swish for 15 seconds, then expectorate; may repeat q2h

Chloraseptic: 5 sprays onto throat or affected area; may repeat q2h

Cepastat: Use up to 2 lozenges q2h PRn

 

Antiseptic Topical

Apply sparse amount gently to affected area once or q8-12hr

 

Pediatric dosage forms and strengths

oral solution (mouthwash/gargle)

• 0.6% (Ulcerease)

oral solution (spray)

• 1.4% (Chloraseptic)

lozenge (oral)

• 14.5mg (Cepastat)

 

Sore Throat

Ulcerease

• <3 years: Not established
• >3 years: Administer as in adults

Chloraseptic

• <2 years: Not established
• 2-12 years: 3 sprays onto throat or affected areas; may repeat q2h
• >12 years: Administer as in adults

Cepastat

• <6 years: Not established
• 6-12 years: 1 lozenge q2h PRN; not to exceed 10 lozenges/24 hours
• >12 years: Administer as in adults

 

Cepastat, Ulcerease (phenol oropharyngeal) adverse (side) effects

Frequency Not Specified

Acute epiglotitis

Edema of the epiglotitis/larynx

 

Warnings

Contraindications

Documented hypersensitivity

 

Cautions

Overdose may cause agitation, confusion, slurred speech, and CNS depression

Do not use for sore >7 days if pain, redness, or irritation continues

 

Pregnancy and lactation

Pregnancy category: C

 

Pregnancy categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

 

Pharmacology of Cepastat, Ulcerease (phenol oropharyngeal)

Mechanism of action

Disinfectant, antiseptic, and local anesthetic

 

Pharmacokinetics

Metabolism: Metabolized to phenylglucuronide and phnyl sulfate, small amounts oxidized to catechol and quinoL

Excretion: Via urine